Posted by Michael Wonder on 28 Apr 2021
Biogen to expand access to its ALS drug, but move may come too late for some patient
27 April 2021 - After weeks of controversy, Biogen has agreed to provide an experimental drug for combating ALS to a small group of very sick patients under a so-called expanded access program.
But the move may come too late for the woman who pushed the company to take this step.
The decision follows sustained pressure by ALS patients, notably Lisa Stockman Mauriello, a health care communications executive who has a rare and fast-moving form of the neurological disease.
